FindTrial
Sign In

Examining the Cost, Benefits, and Safety of Using Dolutegravir as the First Treatment for HIV at a Major Hospital in South Gujarat

Pharmaco-economic variables, effectiveness, and safety of dolutegravir based regimen as a first line ART in people living with HIV at tertiary care hospital of South Gujarat - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062200
Enrollment
100
Registered
2024-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z21- Asymptomatic human immunodeficiency virus [HIV] infection status

Interventions

None listed

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult (=18 years of age) PLHIIV patient of any gender on first line ART for at least 6 months attending ART center

Exclusion criteria

Exclusion criteria: Patient not willing to participate

Design outcomes

Primary

MeasureTime frame
Natural unit of effectiveness, monetary value, Quality adjusted life years and Disability adjusted life yearsTimepoint: After 16 months—

Secondary

MeasureTime frame
CD4 counts & viral load; Adverse drug reaction by analysis of causality, preventability & severity Associated comorbidities with HIVTimepoint: CD4 counts & viral load done at baseline & at six months; Adverse drug reaction by analysis of causality, preventability & severity at the time of reporting—

Countries

India

Contacts

Public ContactDr Brijeshkumar Sojitra

Government Medical College, Surat

drchetnapatel2012@yahoo.com7990618600

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026